ABCELLERA BIOLOGICS INC (ABCL)
CA00288U1066 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 133.32M | 386.50M | 476.10M | 594.10M | 7.60M | |||
| Marketable Securities | 627.26M | 500.00M | 246.80M | 900.00K | 2.10M | |||
| Receivables | 64.38M | 103.40M | 174.90M | 212.30M | 2.30M | |||
| Inventories | 1.11M | 1.50M | 1.70M | N/A | N/A | |||
| Other Current Assets | 45.91M | 34.10M | 30.30M | 6.00M | 700.00K | |||
| Total Current Assets | 871.99M | 1.03B | 929.80M | 813.30M | 12.60M | |||
| Non-Current Assets | ||||||||
| PPE Net | 287.70M | 217.30M | 111.60M | 17.90M | 8.50M | |||
| Investments And Advances | 98.24M | 72.50M | 50.30M | 19.20M | N/A | |||
| Goodwill | 47.81M | 47.80M | 47.80M | 31.50M | N/A | |||
| Intangibles | 120.42M | 131.50M | 148.40M | 115.20M | N/A | |||
| Other Non-Current Assets | 61.94M | 46.30M | 30.60M | 8.40M | 600.00K | |||
| Total Non-Current Assets | 616.11M | 515.40M | 388.80M | 192.20M | 10.90M | |||
| TOTAL ASSETS | 1.49B | 1.54B | 1.32B | 1.01B | 23.50M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 400.00K | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | 200.00K | 2.10M | |||
| Accrued Expenses | 13.87M | 12.00M | 3.70M | 700.00K | 400.00K | |||
| Accounts Payable | 25.51M | 14.80M | 14.90M | 7.10M | 1.60M | |||
| Other Current Liabilities | 79.64M | 91.50M | 102.10M | 95.50M | 3.40M | |||
| Total Current Liabilities | 119.01M | 118.30M | 120.70M | 103.50M | 7.90M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 2.20M | 1.40M | |||
| Deferred Taxes/Income | 30.61M | 33.20M | 37.40M | 26.20M | N/A | |||
| Other Non-Current Liabilities | 186.15M | 156.10M | 134.80M | 43.20M | 4.00M | |||
| Total Non-Current Liabilities | 216.76M | 189.30M | 172.10M | 71.50M | 5.30M | |||
| TOTAL LIABILITIES | 335.78M | 307.60M | 292.80M | 175.00M | 13.20M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | 279.79M | 426.20M | 267.70M | 114.20M | -4.70M | |||
| Additional Paid In Capital | 121.05M | 74.10M | 35.40M | 5.90M | 2.30M | |||
| Common Shares | 753.20M | 734.40M | 722.40M | 710.40M | 12.60M | |||
| Other Shareholders' Equity | -1.72M | -1.40M | 300.00K | N/A | N/A | |||
| Shares Outstanding | 290.82M | 286.90M | 283.30M | 269.50M | 265.60M | |||
| Tangible Book Value per Share | 3.38 | 3.67 | 2.93 | 2.54 | 0.01 | |||
| Total Shareholders' Equity | 1.15B | 1.23B | 1.03B | 830.50M | 10.30M | |||
| TOTAL LIABILITIES AND EQUITY | 1.49B | 1.54B | 1.32B | 1.01B | 23.50M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | 0.00 | 0.17 | |||
| Current Ratio | 7.33 | 8.67 | 7.70 | 7.86 | 1.59 | |||
| Return On Assets (ROA) | -9.84% | 10.29% | 11.64% | 11.82% | -9.36% | |||
| Return On Equity (ROE) | -12.70% | 12.85% | 14.97% | 14.32% | -21.36% | |||
| Return On Invested Capital (ROIC) | N/A | 12.02% | 13.48% | 13.66% | N/A | |||
| Return On Invested Capital Ex Cash (ROICexc) | N/A | 31.90% | 33.99% | 40.14% | N/A | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | N/A | 47.94% | 57.92% | 76.88% | N/A | |||
All data in USD